Repligen (NASDAQ:RGEN) Earns Overweight Rating from Analysts at Wells Fargo & Company
Wells Fargo & Company started coverage on shares of Repligen (NASDAQ:RGEN – Free Report) in a research note published on Tuesday, Marketbeat.com reports. The brokerage issued an overweight rating and a $180.00 price target on the biotechnology company’s stock. Several other equities analysts have also recently issued reports on RGEN. Benchmark restated a hold rating […]
More Stories
Bilt Launches 3 New Credit Cards With 10 Percent Interest Cap for First Year
By Mary Prenon Bilt, one of America’s youngest credit card firms, founded in 2019, is launching a suite of three...
Trump Unveils New Health Care Affordability Plan
By Lawrence Wilson President Donald Trump on Jan. 15 released his administration’s new health care affordability plan, which aims to...
US, Denmark, Greenland to Form Working Group to Find Agreement on Island’s Future
By Ryan Morgam and Emel Akan WASHINGTON—Following a White House meeting on Jan. 14, the foreign ministers of Denmark and...
SEO for Manufacturing Companies: Strategies to Generate High-Quality Leads
SEO has become the biggest part of life in this competitive world. The efficient use of SEO can be done...
The USA “Needs Greenland for the Purpose of National Security”: Trump Remains Adamant
On 14 January, US President Donald Trump declared that “anything less than having Greenland in the hands of the United...
Trump Threatens to Invoke Insurrection Act to End Anti-ICE Protests in Minnesota
By Sam Dorman President Donald Trump has threatened to use the Insurrection Act in Minnesota following an attack on an...